Optimized Treatment of Refractory Hypercholesterolemia in Patients With Atherosclerotic Cardiovascular Disease or Heterozygous Familial Hypercholesterolemia With Alirocumab (OPTIMIZE).
- DOI
- 10.3389/fcvm.2022.953040
- Published
- 2022
- Container
- Frontiers in cardiovascular medicine
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.3389/fcvm.2022.953040,
title = {Optimized Treatment of Refractory Hypercholesterolemia in Patients With Atherosclerotic Cardiovascular Disease or Heterozygous Familial Hypercholesterolemia With Alirocumab (OPTIMIZE).},
author = {Sudano I and Mach F and Moccetti T and Burkard T and Fahe C and Delabays A and Rickli H and Keller PF and Dopheide J and Bodenmann S and Fiolka T and Ehret G and Spirk D},
year = {2022},
journal = {Frontiers in cardiovascular medicine},
doi = {10.3389/fcvm.2022.953040},
url = {https://doi.org/10.3389/fcvm.2022.953040}
}RIS
TY - JOUR TI - Optimized Treatment of Refractory Hypercholesterolemia in Patients With Atherosclerotic Cardiovascular Disease or Heterozygous Familial Hypercholesterolemia With Alirocumab (OPTIMIZE). AU - Sudano I AU - Mach F AU - Moccetti T AU - Burkard T AU - Fahe C AU - Delabays A AU - Rickli H AU - Keller PF AU - Dopheide J AU - Bodenmann S AU - Fiolka T AU - Ehret G AU - Spirk D PY - 2022 JO - Frontiers in cardiovascular medicine DO - 10.3389/fcvm.2022.953040 UR - https://doi.org/10.3389/fcvm.2022.953040 ER -
APA
I, S., F, M., T, M., T, B., C, F., A, D., H, R., PF, K., J, D., S, B., T, F., G, E., & D, S. (2022). Optimized Treatment of Refractory Hypercholesterolemia in Patients With Atherosclerotic Cardiovascular Disease or Heterozygous Familial Hypercholesterolemia With Alirocumab (OPTIMIZE).. Frontiers in cardiovascular medicine. https://doi.org/10.3389/fcvm.2022.953040
Source records
- pubmed · retrieved 2026-09-25T07:18:03.656Z